www.tajpharma.com

Brutravon® is also being investigated by TAJ PHARMA' for use in a variety of other solid tumors, including non-small cell lung cancer, prostate cancer and sarcoma.
Brutravon® injection comes as a solution (liquid) to be given intravenously (into a vein) over 2 to 5 minutes by a doctor or nurse in a medical office, infusion center, or hospital. It is usually given on days 1 and 8 of a 21-day cycle.

Brutravon®
eribulin mesylate
FOR METASTATIC BREAST CANCER/ ADD MORE LIFE
I.V. ADMINISTRATION ONLY (Injection)

Brutravon®

eribulin mesylate
FOR METASTATIC BREAST CANCER/ ADD MORE LIFE
I.V. ADMINISTRATION ONLY (Injection)

Brutravon® (eribulin mesylate) monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

Brutravon® (eribulin mesylate) is a clear, colorless, sterile solution for intravenous administration.
Each vial contains 1 mg of eribulin mesylate as a 0.5 mg/mL solution in ethanol: water (5:95).
Brutravon® is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
Brutravon® is a non-taxane microtubule dynamics inhibitor that is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai.
Brutravon® should be administered in units specialised in the administration of cytotoxic chemotherapy and only under the supervision of a qualified physician experienced in the appropriate use of cytotoxic medicinal products.

Dose delays during therapy
The administration of Brutravon® should be delayed on Day 1 or Day 8 for any of the following:
– Absolute neutrophil count (ANC) < 1 x 109/l
– Platelets < 75 x 109/l
– Grade 3 or 4 non-hematological toxicities.

Brutravon® (eribulin mesylate) Injection, 1 mg/2 mL (0.5 mg/mL). (DOSAGE FORMS AND STRENGTHS)

5 ml type I glass vial, with teflon-coated, butyl rubber stopper and flip-off aluminium over seal, containing 2 ml of solution.
The pack sizes are cartons of 1 or 6 vials.

Food and Drug Administration (FDA) approved .Prescription Only (POM)

Brutravon®
eribulin mesylate
FOR METASTATIC BREAST CANCER/ ADD MORE LIFE
I.V. ADMINISTRATION ONLY (Injection)

A Taj Pharma"India Product